Saturable elimination of piperacillin in critically ill patients: implications for continuous infusionDhaese, S. A. M., Colin, P., Willems, H., Heffernan, A., Gadeyne, B., Van Vooren, S., Depuydt, P., Hoste, E., Stove, C., Verstraete, A. G., Lipman, J., Roberts, J. A. & De Waele, J. J., Dec-2019, In : International journal of antimicrobial agents. 54, 6, p. 741-749 9 p.
Research output: Contribution to journal › Article › Academic › peer-review
The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients. Seventeen critically ill adult patients received continuous and intermittent infusion of piperacillin/tazobactam. Piperacillin plasma concentrations (n = 217) were analysed using population pharmacokinetic (PopPK) modelling. Post-hoc simulations were performed to evaluate the type I error rate associated with the study. Unseen data were used to validate the final model. The mean error (ME) and root mean square error (RMSE) were calculated as a measure of bias and imprecision, respectively. A PopPK model with parallel linear and non-linear elimination best fitted the data. The median and 95% confidence interval (CI) for the model parameters drug clearance (CL), volume of central compartment (V), volume of peripheral compartment (V-p) and intercompartmental clearance (Q) were 9 (7.69-11) L/h, 6.18 (4.93-11.2) L, 11.17 (7.26-12) L and 15.61 (12.66-23.8) L/h, respectively. The Michaelis-Menten constant (K-m) and the maximum elimination rate for Michaelis-Menten elimination (V-max) were estimated without population variability in the model to avoid overfitting and inflation of the type I error rate. The population estimates for K-m and V-max were 37.09 mg/L and 353.57 mg/h, respectively. The bias (ME) was -20.8 (95% CI -26.2 to -15.4) mg/L, whilst imprecision (RMSE) was 49.2 (95% CI 41.2-56) mg/L. In conclusion, piperacillin elimination is (partially) saturable. Moreover, the population estimate for K-m lies within the therapeutic window and therefore saturation of elimination should be accounted for when defining optimum dosing regimens for piperacillin in critically ill patients. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
|Number of pages||9|
|Journal||International journal of antimicrobial agents|
|Publication status||Published - Dec-2019|
- Piperacillin, Pharmacokinetics, Critically ill, Saturation, BETA-LACTAM ANTIBIOTICS, POPULATION PHARMACOKINETIC ANALYSIS, NONLINEAR PHARMACOKINETICS, TAZOBACTAM, PHARMACODYNAMICS, QUANTIFICATION, INTERMITTENT, BOLUS